Literature DB >> 16321982

Different residues mediate recognition of 1-O-oleyllysophosphatidic acid and rosiglitazone in the ligand binding domain of peroxisome proliferator-activated receptor gamma.

Tamotsu Tsukahara1, Ryoko Tsukahara, Satoshi Yasuda, Natalia Makarova, William J Valentine, Patrick Allison, Hongbin Yuan, Daniel L Baker, Zaiguo Li, Robert Bittman, Abby Parrill, Gabor Tigyi.   

Abstract

Here we showed that a naturally occurring ether analog of lysophosphatidic acid, 1-O-octadecenyl-2-hydroxy-sn-glycero-3-phosphate (AGP), is a high affinity partial agonist of the peroxisome proliferator-activated receptor gamma (PPARgamma). Binding studies using the PPARgamma ligand binding domain showed that [32P]AGP and [3H]rosiglitazone (Rosi) both specifically bind to PPARgamma and compete with each other. [32P]AGP bound PPARgamma with an affinity (Kdapp 60 nm) similar to that of Rosi. However, AGP displaced approximately 40% of bound [3H]Rosi even when applied at a 2000-fold excess. Activation of PPARgamma reporter gene expression by AGP and Rosi showed similar potency, yet AGP-mediated activation was approximately 40% that of Rosi. A complex between AGP and PPARgamma was generated using molecular modeling based on a PPARgamma crystal structure. AGP-interacting residues were compared with Rosi-interacting residues identified within the Rosi-PPARgamma co-crystal complex. These comparisons showed that the two ligands occupy partially overlapping positions but make different hydrogen bonding and ion pairing interactions. Site-specific mutants of PPARgamma were prepared to examine individual ligand binding. H323A and H449A mutants showed reduced binding of Rosi but maintained binding of AGP. In contrast, the R288A showed reduced AGP binding but maintained Rosi binding. Finally, alanine replacement of Tyr-473 abolished binding and activation by Rosi and AGP. These observations indicate that the endogenous lipid mediator AGP is a high affinity ligand of PPARgamma but that it binds via interactions distinct from those involved in Rosi binding. These distinct interactions are likely responsible for the partial PPARgamma agonism of AGP.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16321982     DOI: 10.1074/jbc.M510843200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  42 in total

Review 1.  Endogenous ligands for nuclear receptors: digging deeper.

Authors:  Michael Schupp; Mitchell A Lazar
Journal:  J Biol Chem       Date:  2010-10-18       Impact factor: 5.157

2.  Identifying plausible adverse drug reactions using knowledge extracted from the literature.

Authors:  Ning Shang; Hua Xu; Thomas C Rindflesch; Trevor Cohen
Journal:  J Biomed Inform       Date:  2014-07-19       Impact factor: 6.317

Review 3.  Peroxisomes: a nexus for lipid metabolism and cellular signaling.

Authors:  Irfan J Lodhi; Clay F Semenkovich
Journal:  Cell Metab       Date:  2014-02-06       Impact factor: 27.287

4.  Inhibition of the Mitochondrial Pyruvate Carrier by Tolylfluanid.

Authors:  Yana Chen; Kyle S McCommis; Daniel Ferguson; Angela M Hall; Charles A Harris; Brian N Finck
Journal:  Endocrinology       Date:  2018-02-01       Impact factor: 4.736

Review 5.  Lysophosphatidic acid type 2 receptor agonists in targeted drug development offer broad therapeutic potential.

Authors:  Gabor J Tigyi; Leonard R Johnson; Sue Chin Lee; Derek D Norman; Erzsebet Szabo; Andrea Balogh; Karin Thompson; Alyssa Boler; W Shannon McCool
Journal:  J Lipid Res       Date:  2019-01-28       Impact factor: 5.922

6.  New members of the mammalian glycerophosphodiester phosphodiesterase family: GDE4 and GDE7 produce lysophosphatidic acid by lysophospholipase D activity.

Authors:  Noriyasu Ohshima; Takahiro Kudo; Yosuke Yamashita; Stefania Mariggiò; Mari Araki; Ayako Honda; Tomomi Nagano; Chiaki Isaji; Norihisa Kato; Daniela Corda; Takashi Izumi; Noriyuki Yanaka
Journal:  J Biol Chem       Date:  2014-12-20       Impact factor: 5.157

Review 7.  Aiming drug discovery at lysophosphatidic acid targets.

Authors:  Gabor Tigyi
Journal:  Br J Pharmacol       Date:  2010-09       Impact factor: 8.739

8.  Lysophosphatidic acid-induced arterial wall remodeling: requirement of PPARgamma but not LPA1 or LPA2 GPCR.

Authors:  Yunhui Cheng; Natalia Makarova; Ryoko Tsukahara; Huazhang Guo; E Shuyu; Patricia Farrar; Louisa Balazs; Chunxiang Zhang; Gabor Tigyi
Journal:  Cell Signal       Date:  2009-08-23       Impact factor: 4.315

9.  Cyclic AMP-stimulated interaction between steroidogenic factor 1 and diacylglycerol kinase theta facilitates induction of CYP17.

Authors:  Donghui Li; Aarti N Urs; Jeremy Allegood; Adam Leon; Alfred H Merrill; Marion B Sewer
Journal:  Mol Cell Biol       Date:  2007-07-30       Impact factor: 4.272

10.  Sphingosine 1-phosphate pKa and binding constants: intramolecular and intermolecular influences.

Authors:  Mor M Naor; Michelle D Walker; James R Van Brocklyn; Gabor Tigyi; Abby L Parrill
Journal:  J Mol Graph Model       Date:  2007-03-14       Impact factor: 2.518

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.